 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...6263646566676869707172...235236» |
- |||| #GI23 ➡️And, GA underperformed compared to MODERN trials of GA (control arms) ✅️HALO-301 (11.5 mos) ✅️GA + ibrutinib (10.8 mos) Laura Goff was the discussant and presented FOLFIRINOX and NALIRIFOX side by side 🤔Can you actually see any difference? (Twitter) - Jan 20, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
NALIRIFOX = expensive FOLFIRINOX. (Twitter) - Jan 20, 2023
- ||||| Clinical: Finally clear data that fit patients with #PancreaticCancer need triplet chemo. NALIRIFOX > gem➕️abraxane. ❓️is, would FOLFIRINOX do the same? (Twitter) - Jan 20, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
What’s the logic behind including liposomal irinotecan? Do we think of NALIRIFOX as just an improvement of FOLFIRINOX? @IbrahimSahinMD1 @EileenMOReilly @rachnatshroff @drlauragoff @ASCO @SyedAAhmad5 @FlavioRochaMD @DavendraSohal @cancerassassin1 #GI23 (Twitter) - Jan 20, 2023
- |||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Metastases: NAPOLI trial positive for metastatic Pancreatic cancer in first line setting. Less chemo dose but similar efficacy to FOLFIRINOX. A new STANDARD of CARE. @ASCO #ASCOGI23 #PancreaticCancer (Twitter) - Jan 20, 2023
- ||||| Dr. Goff discussant on NAPOLI-3 more diarrhea but less neuropathy likely owing to lower dose of oxali with #NALIRIFOX vs #FOLFIRINOX. Remarkably similar OS but also reinforces that triplet may be superior to gem/abraxane in met #PDAC #pancsm @ASCO #GI23 @OncoAlert (Twitter) - Jan 20, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
NALIRIFOX or FOLFIRINOX #GI23 (Twitter) - Jan 20, 2023
- ||||| Clinical: SPOTLIGHT trial - the addition of zolbetuximab to FOLFOX in 1L treatment of pts w/ CLDN18.2+/HER2- gastric/GEJ cancer results in: ⬆️PFS (10.6 vs 8.6 months, HR 0.75) ⬆️OS (18.2 vs 15.5 months, HR 0.75). How to treat those pts - nivo or zolbe? Some thoughts🧵(1/10): #GI22 (Twitter) - Jan 20, 2023
- ||||| Clinical: #GI23: Napoli-3 of FOLFOX + liposomal irinotecan (NALIRIFOX) vs Gem/abraxane with ⬆️ OS and ⬆️ PFS. #asco23 #cancer #CancerResearch #clinicaltrials @IpsenUS #PancreaticCancer #pancreas @PanCAN https://t.co/fowJ8rZI48 (Twitter) - Jan 20, 2023
- ||||| Clinical: #GI23 NAPOLI-3: NALIRIFOX vs Nab-paclitaxel in mPDAC Met EPs of OS and PFS 🤔 Wondering - how do we select between FOLFIRINOX and NALIRIFOX in 1st line treatment for pts with PDAC? Hope the discussant helps us figure this out! @drlauragoff (Twitter) - Jan 20, 2023
- ||| ✳️NAPOLI-3 trial is positive and improves both OS and PFS compared to gemcitabine abraxane ❗️ ✳️However OS is similar to FOLFIRINOX (11.1 vs 11.1). ❗️ ✳️High rates of diarrhea is not surprising in investigational arm❗️ @OncoAlert (Twitter) - Jan 20, 2023
- || NAPOLI 3 - the closest we will get to a FOLFIRINOX vs. Gem/Abraxane comparison...#GI23 (Twitter) - Jan 20, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
But is it better than FOLFIRINOX…? (Twitter) - Jan 20, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
NALIRIFOX mOS 11.1 months #GI23 NAPOLI-3 FOLFIRINOX mOS 11.1 months (2011) #pancsm @ASCO @OncoAlert (Twitter) - Jan 20, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
The OS in NALIRIFOX is exactly the same as for FOLFIRINOX in the PRODIGE trial. Just saying… (Twitter) - Jan 20, 2023
- |||||| Clinical: .@RutgersCancer’s Dr. Howard Hochster (@HH_Oncodr) & colleagues present “Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel #adenocarcinoma: SWOG S1922” @ASCO #GI23 @RWJBarnabas https://t.co/p9w3nxGMoL (Twitter) - Jan 20, 2023
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Journal: A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. (Pubmed Central) - Jan 20, 2023
Our novel FFX-ΔGEP is, to our knowledge, the first multigene early circulating biomarker that predicts the lack of FOLFIRINOX response after one cycle. Validation in a larger independent patient cohort is crucial before clinical implementation.
- || P2 data, Journal, Metastases: A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). (Pubmed Central) - Jan 20, 2023
GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.
- |||| Clinical, Metastases: SPOTLIGHT trial of #zolbetuximab + mFOLFOX6 improved progression-free and overall survival in patients with CLDN18.2+, HER2- locally advanced unresectable or metastatic gastric/#GEJ adenocarcinoma. #gicsm #GI23 | @KoheiShitara https://t.co/71hfauDro7 (Twitter) - Jan 20, 2023
- ||| Thanks Jason! We also have the RP-6306 PKMYT1 inhibitor trials open at Columbia (with gemcitabine as well as FOLFIRI and ATRi combos) (Twitter) - Jan 20, 2023
- || osemitamab (TST001) / Transcenta
Trial completion date, Trial primary completion date, Monotherapy: TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 20, 2023
P1/2, N=150, Recruiting, Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.
Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy. Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Jun 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jan 20, 2023
P2, N=39, Active, not recruiting, Sponsor: Al B. Benson, III, MD
Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Jun 2024 Trial completion date: Aug 2023 --> Feb 2024 | Trial primary completion date: Dec 2022 --> Jun 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
The #OncoAlertTopTweet 🚨for Day1⃣ #GI23 Tweet @MPishvaian 🇺🇸 @OncoAlert faculty @YJanjigianMD continues to impress and guide us with an update on Checkmate 649♟️which showed a continued improvement in mOS with nivolumab added to FOLFOX‼️ Best, @weoncologists (Twitter) - Jan 20, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
The #OncoAlertTopTweet 🚨for Day1⃣ #GI23 Tweet @GillSharlene 🇨🇦 SPOTLIGHT - FOLFOX +/- Zolbe 1L HER2- mGC/GEJ #GI23 ⭐️ 38.5% CLDN+🎯 📌 mPFS 10.6v8.6m 📌 mOS 18.2v15.5m 📌ORR 60% in both ⬆️N,V w/Zolbe ⭐️ a new SOC for HER2- Congrats to @KoheiShitara Best, @weoncologists (Twitter) - Jan 20, 2023
- ||||| Clinical: The #OncoAlertTopTweet 🚨for Day1⃣ #GI23 Tweet @ASCO Practice-changing Zolbetuximab + mFOLFOX6 meets1⃣ry endpoint in SPOTLIGHT trial🔦 ✅improves PFS, OS in pts w/ CLDN18.2+, HER2-negative, locally adv unresectable/met gastric/GEJ cancer @KoheiShitara Best, @weoncologists (Twitter) - Jan 20, 2023
- ||| NDA: 4-Çalışmada Claudin 18.2 (CLDN18.2) hedefleyen monoklonal antikor olan zolbetuximab standart kemoterapiye (mFOLFOX6) eklendi. Spesifik olarak, zolbetuximab eklenmesi, sadece kemoterapiye göre kansere bağlı ilerleme veya ölüm riskini %24,9 oranında azalttı.✅ (Twitter) - Jan 19, 2023
- |||||| Clinical, Metastases: Primary results SPOTLIGHT study: Zolbetuximab + mFOLFOX6 as first-line treatment for patients with claudin-18.2+ / HER2− unresectable or metastatic gastric or GEJ adenocarcinoma #GI23 ⬆️PFS: 10.6 vs 8.6 m ⬆️OS: 18.2 vs 15.5 m @ASCO @OncoAlert https://t.co/ApPeq6TbYy (Twitter) - Jan 19, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Leucovorin is also obsolete, so why do trials still include it when bolus 5FU is omitted? (Twitter) - Jan 19, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
NeoAdyuvancia en CÁNCER DE COLON (FOX-TROT) sale a luz. FOLFOX 4 ciclos —CX —-> FOLFOX 8 ciclos (Twitter) - Jan 19, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Surgery: 🔥🔥🔥Thread by Dr. @JenSeligmann describing the just published FOxTROT trial! 👏🏼👏🏼 T3-4NxM0 colon cancer 3c neoadjuvant FOLFOX, compared with upfront surgery, ⬇️ risk of residual or recurrent disease within 2 years: 16.9% vs. 21.5%, P = .037. https://t.co/qR2LrpGieX (Twitter) - Jan 19, 2023
- ||||||| Clinical: SPOTLIGHT (PhIII): Zolbetuximab (anti-CLDN18.2) + mFOLFOX6 improves PFS and OS in pts w/ HER-2 neg Claudin-18.2+(~38% pts) mGC / GEJ ADC @OncoAlert @ASCO #ascogi23 (Twitter) - Jan 19, 2023
- ||||| Metastases: Frontline Zolbetuximab/mFOLFOX6 Prolongs Survival in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma @KoheiShitara @ASCO #GI23 https://t.co/skplT1p1fV (Twitter) - Jan 19, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Metastases: Are you referring to omission of bolus 5FU w FOLFOX in metastatic setting, adjuvant setting or both? In the curative setting I try to stick with the Mosaic trial exactly as it was written. In stage four setting, thoughts about this? Thanks a lot. (Twitter) - Jan 19, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zolbetuximab (IMAB362) / Astellas
Congrats! @KoheiShitara & #GastricCancer world #SPOTLIGHT P3 (+) trial for Zolbetuximab + FOLFOX vs. FOLFOX in mG/GEJ adenoca. (mostly PD-L1 CPS<5%) PFS HR 0.75 🔥 mOS 18.2 vs 15.5 HR 0.75👇🏼Other ongoing CLDN18.2 targeting trials for #PancreaticCancer @MSKCancerCenter @CpcrMsk (Twitter) - Jan 19, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
SPOTLIGHT - FOLFOX +/- Zolbe 1L HER2- mGC/GEJ ⭐️ 38.5% CLDN+🎯 📌 mPFS 10.6v8.6m HR 0.75 ✅ 📌 mOS 18.2v15.5m HR 0.75 ✅ 📌ORR 60% in both ⬆️N,V w/ Zolbe ⭐️ a new SOC for HER2- Question will be IO vs Zolbe? Should we stratify by PDL1CPS? Congrats to @KoheiShitara etal @OncoAlert (Twitter) - Jan 19, 2023
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Good point. mFOLFOX6 in Spotlight control arm performed significantly better that one would expect. ORR 60% and mOS 15 months?! (Twitter) - Jan 19, 2023
- ||||| Biomarker, Clinical, IO biomarker, Metastases: #SPOTLIGHT data by @KoheiShitara at #GI23: #Zolbetuximab+mFOLFOX6 as 1L for CLDN18.2+ HER2- advanced GC/GEJ ⬆️PFS and OS ↔️ORR ▶️TEAEs: nausea/vomiting (on target) ▶️CLDN18.2+ in 38.5% of pts, and PD-L1 CPS≥5 in 13.2% First positive biomarker-selected ph3 trial in GC in>10 years (Twitter) - Jan 19, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zolbetuximab (IMAB362) / Astellas
#GI23 Zolbetuximab + FOLFOX is a new standard for 1L Claudin18.2+/HER2- adv Gastric/GEJx adenoCA. Some increased GI toxicity. @CathyEngMD @pashtoonkasi @GillSharlene @FlavioRochaMD @DucreuxMichel @FlorianLordick (Twitter) - Jan 19, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Metastases: Nivo/FOLFOX continues to be a clear winner for first line metastatic gastric and GEJ cancer (I’m guessing in HER2 (-) and Claudin18.2 negative diseases only moving forward) @YJanjigianMD #gi23 (Twitter) - Jan 19, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
SPOTLIGHT - FOLFOX +/- Zolbe 1L HER2- mGC/GEJ #GI23 ⭐️ 38.5% CLDN+🎯 📌 mPFS 10.6v8.6m HR 0.75 ✅ 📌 mOS 18.2v15.5m HR 0.75 ✅ 📌ORR 60% in both ⬆️N,V w/ Zolbe ⭐️ a new SOC for HER2- Question will be IO vs Zolbe? - stratify by PDL1? Congrats to @KoheiShitara etal @OncoAlert https://t.co/Srg9NgIAK6 (Twitter) - Jan 19, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS
#GI23 ➡️ @YJanjigianMD continues to impress and guide us with an update on Checkmate 649 which showed a continued improvement in mOS with nivolumab added to FOLFOX. 21% long term survivors in the CPS>=5 group....that's awesome‼️ (Twitter) - Jan 19, 2023
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
SPOTLIGHT - FOLFOX +/- Zolbe 1L HER2- mGC/GEJ ⭐️ 38.5% CLDN+🎯 📌 mPFS 10.6v8.6m HR 0.75 ✅ 📌 mOS 18.2v15.5m HR 0.75 ✅ 📌ORR 60% in both arms ⬆️N,V with Zolbe ⭐️ a new SOC for HER2- Question will be IO vs Zolbe? Should we stratify by PDL1CPS? Congrats to @KoheiShitara etal (Twitter) - Jan 19, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
interesting to see the control group did better than the historical group of FOLFOX or even the control group in checkmate 649 (Twitter) - Jan 19, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zolbetuximab (IMAB362) / Astellas
Clinical, Metastases: GI ASCO 2023, first scoop: Zolbetuximab + FOLFOX clearly better than FOLFOX in metastatic gastric cancer. A vast majority of the patients were CPS<5. Main toxicity: nausea vomiting (Claudin is present in the stomach...). Great success!! (Twitter) - Jan 19, 2023
- |||| Clinical: #SPOTLIGHT presented at #GI23 Improved PFS w zolbetuximab/mFOLFOX6 vs placebo/mFOLFOX6 (med 10.6m vs 8.7m) for patients w LA or mG/GEJ gastric cancer w CLDN.18.2+/HER2- disease OS also improved (HR 0.75, p=0.0053), benefit seen beyond 8m @OncoAlert @oncologytube (Twitter) - Jan 19, 2023
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zolbetuximab (IMAB362) / Astellas
#GI23 ➡️@KoheiShitara gave the highly anticipated presentation of FOLFOX +/- zolbetuximab for Claudin 18.2➕️gastric/GEJ jxn Ca ~3 mo⬆️in mOS, achieving an 18.2 month mOS - the longest ever in a🌏study 👏to the investigators for changing the standard of care‼️ (Twitter) - Jan 19, 2023
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., zolbetuximab (IMAB362) / Astellas
Clinical, P3 data: Results from Phase 3 SPOTLIGHT trial for the role for Claudin 18.2 with Zolbetuximab + FOLFOX for HER2 gastric #cancer with ⬆️ PFS and ⬆️ OS!! 👏🏻 @AstellasUS #ascogi23 #ascogi #cancer #CancerResearch #ClinicalTrials @OncoAlert (Twitter) - Jan 19, 2023
- ||||| Clinical: 🔥Zolbetuximab + mFOLFOX6 as 1L treatment for CLDN18.2+ #gastriccancer @ACCO GU 2023 ✅SPOTLIGHT 🗺️phs-III, 550pts 👉ORR 60.1 vs 60.2% 👉PFS 10.6 vs 8.7 HR 0.75 👉OS 18.23 vs 15.54, Herzlichen Gruß 0.75 👉acceptable safety, mainly nausea ✅new option for🎯💊 @myESMO @OncoAlert (Twitter) - Jan 19, 2023